Poliovirus receptor(PVR,CD155)has recently been gaining scientific interest as a therapeutic target in the field of tumor immunology due to its prominent endogenous and immune functions.In contrast to healthy tissues,...Poliovirus receptor(PVR,CD155)has recently been gaining scientific interest as a therapeutic target in the field of tumor immunology due to its prominent endogenous and immune functions.In contrast to healthy tissues,PVR is expressed at high levels in several human malignancies and seems to have protumorigenic and therapeutically attractive properties that are currently being investigated in the field of recombinant oncolytic virotherapy.More intriguingly,PVR participates in a considerable number of immunoregulatory functions through its interactions with activating and inhibitory immune cell receptors.These functions are often modified in the tumor microenvironment,contributing to tumor immunosuppression.Indeed,increasing evidence supports the rationale for developing strategies targeting these interactions,either in terms of checkpoint therapy(i.e.,targeting inhibitory receptors)or in adoptive cell therapy,which targets PVR as a tumor marker.展开更多
基金SJ.is supported by the grant "Strengthening the capacity of CerVirVac for research in virus immunology and vaccinology",KK.01.1.1.01.0006,awarded to the Scientific Centre of Excellence for Virus Immunology and Vaccines and co-financed by the European Regional Development FundP.K.B.and T.L.R.are supported by the Croatian Science Foundation (HRZZ) under project number 1533.
文摘Poliovirus receptor(PVR,CD155)has recently been gaining scientific interest as a therapeutic target in the field of tumor immunology due to its prominent endogenous and immune functions.In contrast to healthy tissues,PVR is expressed at high levels in several human malignancies and seems to have protumorigenic and therapeutically attractive properties that are currently being investigated in the field of recombinant oncolytic virotherapy.More intriguingly,PVR participates in a considerable number of immunoregulatory functions through its interactions with activating and inhibitory immune cell receptors.These functions are often modified in the tumor microenvironment,contributing to tumor immunosuppression.Indeed,increasing evidence supports the rationale for developing strategies targeting these interactions,either in terms of checkpoint therapy(i.e.,targeting inhibitory receptors)or in adoptive cell therapy,which targets PVR as a tumor marker.
